Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | GRM5 | P41594 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30212560 | 1.00 | P2RX7 (0.59) | P2RX7CYP1A2SMN1; SMN2RAB9ANPC1 | |
| Hydrochloric Acid SCHEMBL5728855 | 0.98 | P2RX7 (0.58) | P2RX7CYP1A2SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL24581364 | 0.89 | CCR1 (0.55) | P2RX7CYP1A2SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL69653 | 0.87 | MAPT (0.64) | CYP1A2SMN1; SMN2RAB9ANPC1TP53 | |
| SCHEMBL31325221 | 0.87 | MAPT (0.49) | P2RX7CYP1A2SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL10759567 | 0.82 | GRM5 (0.54) | P2RX7CYP1A2SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL20475333 | 0.82 | MAPT (0.51) | CYP1A2SMN1; SMN2RAB9ANPC1TP53 | |
| SCHEMBL13681299 | 0.82 | P2RX7 (0.53) | P2RX7CYP1A2SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL16049654 | 0.82 | P2RX7 (0.58) | P2RX7CYP1A2SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL23037197 | 0.82 | MAPT (0.54) | CYP1A2SMN1; SMN2RAB9ANPC1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 461 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113649055-B | Catalyst for selective hydrogenation of methyl picolinate and preparation method and application thereof | 湖北大学 | 2023-03-24 | — | — | CN | claimed |
| CN-113649055-A | Catalyst for selective hydrogenation of methyl picolinate and preparation method and application thereof | 湖北大学 | 2021-11-16 | — | — | CN | claimed |
| EP-3112352-A1 | OPIOID RECEPTOR MODULATORS | Janssen Pharmaceutica NV (BE) | 2017-01-04 | — | — | EP | claimed |
| EP-1725537-B1 | NOVEL COMPOUNDS AS OPIOID RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-07-13 | — | — | EP | claimed |
| WO-2026098560-A2 | BENZENE-CONTAINING POLYCYCLIC DERIVATIVE MODULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翰森生物医药科技有限公司 | 2026-05-15 | — | — | WO | disclosed |
| US-20260049159-A1 | ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES | SYNTHIS THERAPEUTICS, INC. (US) | 2026-02-19 | — | — | US | disclosed |
| US-12528815-B2 | 5-amino-8-(4-pyridyl)-[1,2,4]triazolo[4,3-c]pyrimidin-3-one compounds for use against cancer | NXERA PHARMA UK LIMITED (GB) | 2026-01-20 | — | — | US | disclosed |
| US-12473377-B2 | Antibody-ALK5 inhibitor conjugates and their uses | SYNTHIS THERAPEUTICS, INC. (US) | 2025-11-18 | — | — | US | disclosed |
| US-20250339425-A1 | Alpha9 and Alpha7 Nicotinic Acetylcholine Receptor Ligands | UNIV NORTHEASTERN (US) | 2025-11-06 | — | — | US | disclosed |
| EP-4232431-B1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY | LHOTSE BIO INC (US) | 2025-08-13 | — | — | EP | disclosed |
| US-20250215017-A1 | TGF-ß INHIBITOR COMPOUND AND USE THEROF | MEDINNO PHARMACEUTICAL TECHNOLOGY (ZHUHAI) CO., LTD. (CN) | 2025-07-03 | — | — | US | disclosed |
| US-20250179094-A1 | TGF-B INHIBITOR COMPOUND AND USE THEREOF | MEDINNO PHARMACEUTICAL TECHNOLOGY (ZHUHAI) CO., LTD. (CN) | 2025-06-05 | — | — | US | disclosed |
| US-6476021-B1 | Compounds having cGMP-PDE inhibitory effect | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2002-11-05 | — | — | US | disclosed |
| WO-2002066462-A1 | PYRAZOLE DERIVATIVES AGAINST TGF OVEREXPRESSION | GLAXO GROUP LIMITED (GB) | 2002-08-29 | — | — | WO | disclosed |
| WO-2002062776-A1 | 2-AMINO-4-(PYRIDIN-2-YL)-THIAZOLE DERIVATIVES AS TRANSFORMING GROWTH FACTOR BETA (TGF-BETA) INHIBITORS | GLAXO GROUP LIMITED (GB) | 2002-08-15 | — | — | WO | disclosed |
| WO-2002062787-A1 | PYRAZOLES AS TGF INHIBITORS | GLAXO GROUP LIMITED (GB) | 2002-08-15 | — | — | WO | disclosed |
| WO-2002062794-A2 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2002-08-15 | — | — | WO | disclosed |
| EP-1048666-A1 | NOVEL COMPOUNDS HAVING cGMP-PDE INHIBITORY EFFECT | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2000-11-02 | — | — | EP | disclosed |
| US-5114945-A | Spiropiperidine derivatives | GLAXO GROUP LIMITED (GB) | 1992-05-19 | — | — | US | disclosed |
| EP-0330461-A2 | Piperidine derivatives | GLAXO GROUP LIMITED (GB) | 1989-08-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250339425-A1 | Alpha9 and Alpha7 Nicotinic Acetylcholine Receptor Ligands | CHRNA9, CHRNA7, CHRNA1 | P2RX7 19/4885CYP1A2 1668/4885SMN1; SMN2 2910/4885 |
| US-20250179094-A1 | TGF-B INHIBITOR COMPOUND AND USE THEREOF | TGFB1, TGFB2, TGFBR1 | P2RX7 3502/4885CYP1A2 2051/4885SMN1; SMN2 3437/4885 |
| US-12473377-B2 | Antibody-ALK5 inhibitor conjugates and their uses | ALK, ALKBH5, ALKBH3 | P2RX7 4265/4885CYP1A2 2565/4885SMN1; SMN2 3523/4885 |
| US-20260049159-A1 | ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES | ALK, CD2, TGFBR2 | P2RX7 3684/4885CYP1A2 3047/4885SMN1; SMN2 3447/4885 |
| US-12528815-B2 | 5-amino-8-(4-pyridyl)-[1,2,4]triazolo[4,3-c]pyrimidin-3-one compounds for use against cancer | ADORA1, ADORA3, OPRL1 | P2RX7 55/4885CYP1A2 1308/4885SMN1; SMN2 1824/4885 |
| US-20250215017-A1 | TGF-ß INHIBITOR COMPOUND AND USE THEROF | TGFB1, TGFB2, TGFBR2 | P2RX7 3750/4885CYP1A2 3248/4885SMN1; SMN2 3159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.